Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
407,379

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HSIC or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. MMSI: Which Stock Is the Better Value Option?

    Zacks Equity Research

    Are Options Traders Betting on a Big Move in Merit Medical (MMSI) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Merit Medical (MMSI) stock based on the movements in the options market lately.

      Zacks Equity Research

      Implied Volatility Surging for Merit Medical (MMSI) Stock Options

      by Zacks Equity Research

      Merit Medical (MMSI) needs investors to pay close attention to the stock based on moves in the options market lately.

        Zacks Equity Research

        Medical - Dental Supplies Outlook: Long-Term Prospects Bright

        by Zacks Equity Research

        The ongoing digital transition is posing challenges to dental industry players in the wake of growing oral hygiene awareness and increasing incidence of dental diseases.

          Zacks Equity Research

          Why Is Merit Medical (MMSI) Up 1% Since Last Earnings Report?

          by Zacks Equity Research

          Merit Medical (MMSI) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

            Zacks Equity Research

            COO or MMSI: Which Is the Better Value Stock Right Now?

            by Zacks Equity Research

            COO vs. MMSI: Which Stock Is the Better Value Option?

              Zacks Equity Research

              Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance

              by Zacks Equity Research

              Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.

                Zacks Equity Research

                AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife

                by Zacks Equity Research

                AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.

                  Zacks Equity Research

                  Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?

                  by Zacks Equity Research

                  Merit Medical's (MMSI) acquisition-driven strategy to boost growth by expanding existing product offerings across all business segments in Q2.

                    Zacks Equity Research

                    HSIC or MMSI: Which Is the Better Value Stock Right Now?

                    by Zacks Equity Research

                    HSIC vs. MMSI: Which Stock Is the Better Value Option?

                      Zacks Equity Research

                      Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed

                      by Zacks Equity Research

                      Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed

                        Zacks Equity Research

                        7 GARP Stocks to Scoop Up for Maximum Returns

                        by Zacks Equity Research

                        Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

                          Zacks Equity Research

                          Here's Why You Should Hold Merit Medical (MMSI) Stock Now

                          by Zacks Equity Research

                          Here we take a quick look at the major factors that plague Merit Medical (MMSI) and discuss the prospects that ensure near-term recovery.

                            Zacks Equity Research

                            Merit Medical (MMSI) Up 18.9% in a Month on Solid Q1 Earnings

                            by Zacks Equity Research

                            Merit Medical (MMSI) reports strong Q1 earnings and sees solid growth across segments and geographies.

                              Zacks Equity Research

                              Zacks.com highlights: VMware, PetMed Express, Merit Medical Systems, Dollar General and inTEST

                              by Zacks Equity Research

                              Zacks.com highlights: VMware, PetMed Express, Merit Medical Systems, Dollar General and inTEST

                                Zacks Equity Research

                                Can High Revenues Aid SBA Communications (SBAC) Q1 Earnings?

                                by Zacks Equity Research

                                While higher consolidated revenues might benefit SBA Communications (SBAC) in Q1 earnings, its financials are likely to be affected by high customer concentration & consolidation in wireless industry.

                                  Zacks Equity Research

                                  Nokia (NOK) to Report Q1 Earnings: What's in the Cards?

                                  by Zacks Equity Research

                                  Higher revenues are likely to aid Nokia (NOK) to surpass earnings estimates in the to-be-reported quarter.

                                    Zacks Equity Research

                                    What to Expect From International Paper (IP) in Q1 Earnings?

                                    by Zacks Equity Research

                                    Despite contraction in gross estimated revenues figure, can International Paper (IP) beat market estimates in this quarter? Here are some clues for investors.

                                      Zacks Equity Research

                                      What Makes Patterson Companies (PDCO) a Strong Sell?

                                      by Zacks Equity Research

                                      Patterson Companies (PDCO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

                                        Zacks Equity Research

                                        Becton, Dickinson (BDX), Bard Receive Regulatory Nod in China

                                        by Zacks Equity Research

                                        Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.

                                          Zacks Equity Research

                                          Is a Beat in Store for Walgreens Boots (WBA) in Q1 Earnings?

                                          by Zacks Equity Research

                                          Walgreens Boots' (WBA) Retail Pharmacy USA division continues to witness comparable prescription growth as well as a robust retail prescription market.

                                            Zacks Equity Research

                                            Becton, Dickinson (BDX) a Step Closer to Bard Acquisition

                                            by Zacks Equity Research

                                            Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.

                                              Zacks Equity Research

                                              Merit Medical Deserves a Place in Your Portfolio: Here's Why

                                              by Zacks Equity Research

                                              A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.

                                                Zacks Equity Research

                                                Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak

                                                by Zacks Equity Research

                                                Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.

                                                  Zacks Equity Research

                                                  Only 4 Dental Stocks to Buy Amid MedTech Regulatory Woes

                                                  by Zacks Equity Research

                                                  After a stellar five-year run on the bourse, the performance of the dental industry has taken a hit in the last two years.